Clinical Trials Browser

Phase 2 × Recurrence × talazoparib × Clear all

NCT02286687 2026-01-02

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

Phase 2 Active not recruiting

Neoplasm Metastasis, Neoplasms, Recurrence